According to Takeda, TAK-379 is an anti-diabetic agent categorized as an insulin sensitizer and was in the Phase II stage of development in the US and Europe, and in the Phase I stage of development in Japan, respectively. However, the company has concluded that TAK-379’s profile does not meet the internal criteria to support continuation of further development activities.
The company said that it will continue to work for enhancing its R&D pipeline through in-house R&D activities; supported by in-licensing and alliance activities and product life cycle management; pursuing the earliest possible submission and approval of the mainstay products of the next generation which are in the late clinical development stage.